Evolus, Inc.
Evolus, Inc. (NASDAQ: EOLS) is a global performance beauty company focused on the cash-pay aesthetic market, delivering injectable products for medical aesthetic practitioners and their consumers. The company operates at www.evolus.com and maintains operations across the United States, Canada, Europe, and Australia… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Evolus, Inc. does
In the company’s own words
Evolus, Inc. (NASDAQ: EOLS) is a global performance beauty company focused on the cash-pay aesthetic market, delivering injectable products for medical aesthetic practitioners and their consumers. The company operates at www.evolus.com and maintains operations across the United States, Canada, Europe, and Australia with 334 full-time employees as of December 31, 2025.
The company's primary product portfolio comprises two major categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid gels. Jeuveau®, the company's flagship neurotoxin product, is a proprietary 900 kilodalton botulinum toxin type A formulation indicated for temporary improvement of moderate to severe glabellar lines in adults. Approved in the United States, Canada, European markets, Australia, and Switzerland, Jeuveau® is supported by the TRANSPARENCY global clinical program encompassing over 2,100 patients, including head-to-head Phase III data comparing it to BOTOX. The Evolysse™ collection represents the company's injectable hyaluronic acid gel line utilizing first-generation cold technology, with products addressing mid-face, nasolabial folds, lips, and eye areas. Evolysse™ Form and Evolysse™ Smooth received FDA approval in February 2025 and launched in the United States in April 2025. The company obtained European Union regulatory approval for four Evolysse™ products in October 2024, with European launch anticipated in the second quarter of 2026.
The company manufactures Jeuveau® through Daewoong Pharmaceutical Co. Ltd., a major South Korean pharmaceutical manufacturer, under an exclusive license agreement. Evolysse™ is manufactured by Symatese S.A.S., a French biomaterials company with over a decade of hyaluronic acid gel manufacturing experience. The company's strategic differentiation centers on pursuing an aesthetic-only, non-reimbursed product strategy, leveraging a differentiated digital platform for customer engagement, and building a diversified product offering through licensing and partnerships. The addressable market for Jeuveau® is estimated at $3.2 billion in the United States and $1.1 billion in addressable countries, while Evolysse™ represents $1.3 billion in the United States and $0.9 billion in addressable countries as of 2028 projections.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NEWPORT BEACH, CA
- Fiscal year end
- December
- CIK
- 1570562
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Evolus, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Evolus, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Evolus, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Evolus, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Evolus, Inc.'s last four quarterly filings that the numbers alone won't show?”